CCL5 and myeloid sarcoma: Moreover, the obtained analytical characteristics fulfilled the requirements for application to real clinical samples, as was demonstrated by determining the CCL5 endogenous content in 100-fold diluted sera from healthy individuals and patients diagnosed with MS, with no further sample treatment in an assay time of two hours.